Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some claims align with the provided label excerpts (e.g., premature discontinuation warning and neuraxial/epidural hematoma counseling). However, many other claims are not verifiable from the supplied label excerpts, and several safety/clinical guidance statements are not supported by the provided text.
Category Scores
Accurate Statements
The boxed-style warnings excerpted (“Premature discontinuation…”, “Spinal/Epidural hematoma”) explicitly refer to ELIQUIS and describe effects of apixaban in the context of oral anticoagulant use and neuraxial procedures.
Warnings and Precautions (5.1) and (5.3) excerpts provided; Medication Guide and patient counseling excerpt provided in prompt.
Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events.
Warnings and Precautions (5.1) provided in prompt.
When neuraxial anesthesia or spinal/epidural puncture is employed, patients treated with antithrombotic agents are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis.
Warnings and Precautions (5.3) provided in prompt.
Patients should not discontinue ELIQUIS without talking to their physician first.
Patient Counseling excerpt in prompt: “Not to discontinue ELIQUIS without talking to their physician first.”
If any signs or symptoms of spinal or epidural hematomas occur, advise the patient to seek emergent medical attention.
Patient Counseling excerpt in prompt: “If any of these symptoms occur, advise the patient to seek emergent medical attention.”
Unsupported Statements
Apixaban helps prevent blood clots by reducing the activity of a key clotting factor involved in forming fibrin clots.
Mechanism/fibrin-clot formation explanation is not present in the provided label excerpts.
Apixaban is used to lower the risk of thromboembolic events.
Indication-specific statements are not supported by the provided excerpts.
Apixaban is used in common real-world settings such as atrial fibrillation.
No indication text (e.g., atrial fibrillation) is included in the provided excerpts beyond a brief mention in the 5.1 trial transition context; this does not substantiate a general “used in atrial fibrillation” claim.
Apixaban is used for treatment/prevention of venous clots.
No venous thromboembolism indication text is provided in the excerpts.
The specific indication depends on the approved dosing regimen in the product’s labeling.
No dosing regimen/indication mapping is included in the provided excerpts.
Apixaban directly inhibits Factor Xa.
The provided excerpts do not explicitly describe direct Factor Xa inhibition (the prompt only includes a general description: “apixaban (factor Xa inhibitor)” in the user-provided context, not in the label excerpts).
Blocking Factor Xa reduces thrombin generation.
Not present in provided label excerpts.
Reducing thrombin generation helps prevent clot formation.
Not present in provided label excerpts.
The right apixaban dose depends on the indication and patient factors such as kidney function and other clinical characteristics.
Kidney-function dosing adjustment guidance is not included in the provided excerpts.
Changes in kidney function can affect whether apixaban dosing needs adjustment.
Not present in provided excerpts.
Drug interactions can affect whether apixaban dosing needs adjustment.
No interaction/dose adjustment guidance is provided in the provided excerpts.
Bleeding history and planned procedures often affect whether apixaban dosing needs adjustment.
No dosing adjustment rules for bleeding history are provided in the excerpts.
The main risk with apixaban is bleeding.
The provided excerpts discuss thrombotic risk after discontinuation and spinal/epidural hematoma; they do not support a statement that “the main risk” is bleeding.
Patients should seek urgent care for signs of serious bleeding while taking apixaban.
Patient counseling excerpt provided is specifically about spinal/epidural hematoma signs, not general bleeding signs.
Serious bleeding signs while taking apixaban include heavy or uncontrolled bleeding, black/tarry stools, vomiting blood, unusual bruising.
These specific symptom examples are not included in the provided label excerpts.
Medication interactions are a major concern with anticoagulants.
No such interaction emphasis is provided in the excerpts.
Drugs that affect how apixaban levels change in the body can increase bleeding risk.
No pharmacokinetic interaction details are provided in the excerpts.
Drugs that affect how apixaban levels change in the body can reduce apixaban effectiveness.
No such interaction/efficacy effect is provided in the excerpts.
Certain antifungals/antibiotics and other agents that alter bleeding risk can change apixaban levels.
No drug class examples are provided in the excerpts.
Any new prescription or over-the-counter medicine should be reviewed with a clinician or pharmacist for apixaban interactions.
No general “review all new OTC meds” counseling is present in the provided excerpts.
Stopping or holding apixaban before surgery or dental work depends on the bleeding risk from the procedure and the patient’s clotting risk.
No pre-procedure stopping guidance for surgery/dental work is provided in the excerpts.
Clinicians use a tailored plan rather than a one-size-fits-all approach for stopping/holding apixaban before procedures.
Not present in the provided excerpts.
Patent and exclusivity timing can affect when generic versions or market alternatives become available for Eliquis (apixaban).
Not a prescribing-information claim and not supported by the provided label excerpts.
Alternatives to Eliquis (apixaban) include other anticoagulants used for similar indications.
No comparative alternatives text is provided in the excerpts.
Alternatives may include different factor Xa inhibitors depending on the patient’s situation.
No alternatives comparison is provided in the excerpts.
Switching anticoagulants generally requires clinician guidance because risks, dosing schedules, and interaction profiles differ by drug.
While some conversion guidance exists in the dosing section excerpt (2.5), the generalized claim about switching “generally” is not fully supported by provided excerpts.
Contradictions
Important Omissions
Specific boxed-warning content and/or spinal/epidural catheter timing details (e.g., “not removed earlier than 24 hours,” “next dose not earlier than 5 hours,” “delay 48 hours after traumatic puncture”) were not captured by the challenged claims.
Importance:
Moderate
Monitoring specifics for neurologic impairment after neuraxial anesthesia (e.g., numbness/weakness, bowel/bladder dysfunction) were not included in the set of claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some label-aligned counseling about not discontinuing without speaking to a physician and seeking emergent attention for spinal/epidural hematoma symptoms is present. However, many other claims about dosing, interactions, and specific serious bleeding symptom examples are unsupported by the provided label excerpts, increasing the chance of inaccurate patient-facing guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Large portions of the claims are not supported by the provided label excerpts (indications, mechanism, dosing adjustments, interaction specifics, and general bleeding symptom lists).
Suggested Improvement
Limit claims to text supported by the supplied label excerpts (Warnings 5.1 and 5.3 and Patient Counseling). If evaluating additional label content (e.g., full indications, dosing, contraindications, drug interactions, and patient bleeding counseling), provide the corresponding label sections.